Perspectives on the management of chronic hepatitis B and C

Dusheiko, Geoffrey; Jacobs, Michael

doi:10.1586/eri.09.16

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances in the understanding of the structure and life cycle of HCV have accelerated the development of potential novel therapeutic strategies. In addition to protease inhibitors, nucleoside and non-nucleoside polymerase inhibitors, NS5a inhibitors, cyclophilin inhibitors and immunomodulatory therapies including Toll-like-receptor agonists and entry inhibitors are being developed [34]. Although RBV may remain an integral part of next generation therapeutic regimens, there is a realistic possibility of developing PEG IFN-free oral combinations.…”

Section: Five-year Viewmentioning

confidence: 99%

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection

Trembling¹,

Tanwar²,

Dusheiko³

2012

Expert Review of Anti-infective Therapy

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis C (CHC) virus infection affects more than 170 million people globally. The aim of treatment of CHC is to affect sustained elimination of the virus (a sustained virological response [SVR]). The success and duration of therapy with interferon is dependent on HCV genotype. The current standard of care comprises combined treatment with pegylated interferon and ribavirin. Rates of SVR in patients with genotype 1 infection, the least responsive group, are less than 50%. Boceprevir is a ketoamide protease inhibitor that binds reversibly to the HCV nonstructural NS3 protease active site inhibiting intracellular viral replication. Phase III clinical studies have demonstrated that, in combination with the current standard of care, boceprevir significantly increases the SVR rate in both treatment-naive and previously treated patients with genotype 1 CHC. Both the US FDA and EMA have approved boceprevir for the treatment of genotype 1 CHC: the first directly-acting antiviral drug to be licensed for this indication. This article will review the pharmacology and pharmacodynamics of boceprevir, the efficacy and safety of the drug, and explore possible future developments in the management of CHC.

show abstract

Section: Five-year Viewmentioning

confidence: 99%